EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 24-WEEK STUDY

被引：1
|
作者：
Xu, D. [1 ]
Zhang, S. [1 ]
Huang, C. [2 ,3 ]
Huang, C. [2 ,3 ]
Qin, L. [4 ]
Li, X. [5 ]
Chen, M. [6 ]
Liu, X. [7 ]
Liu, Y. [8 ]
Li, Z. [9 ]
Hu, J. [10 ]
Bao, C. [11 ]
Wei, W. [12 ]
Tian, J. [13 ]
Duan, X. [14 ]
Van Vollenhoven, R. [15 ]
Fang, J. [16 ,17 ]
Zeng, X. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Rheumatol, Beijing, Peoples R China
[2] Beijing Hosp, Rheumatol, Beijing, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 2, Rheumatol, Guangzhou, Peoples R China
[4] Huzhou Third Municipal Hosp, Rheumatol, Huzhou, Peoples R China
[5] Anhui Prov Hosp, Rheumatol, Hefei, Anhui, Peoples R China
[6] Xiamen Univ, Affiliated Hosp 1, Rheumatol, Xiamen, Peoples R China
[7] Shanxi Med Univ, Hosp 1, Rheumatol, Taiyuan, Shanxi, Peoples R China
[8] Sichuan Univ, West China Hosp, Rheumatol, Chengdu, Sichuan, Peoples R China
[9] Bengbu Med Coll, Affiliated Hosp 1, Rheumatol, Bengbu, Peoples R China
[10] Jiangxi Pingxiang Peoples Hosp, Rheumatol, Jianxi, Peoples R China
[11] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Rheumatol, Shanghai, Peoples R China
[12] Tianjin Med Univ, Gen Hosp, Rheumatol, Tianjin, Peoples R China
[13] Cent South Univ, Xiangya Hosp 2, Rheumatol, Xiangya, Peoples R China
[14] Nanchang Univ, Affiliated Hosp 2, Rheumatol, Nanchang, Jiangxi, Peoples R China
[15] Univ Amsterdam, Rheumatol, Med Ctr, Amsterdam, Netherlands
[16] Shanghai Tongi Univ, Rheumatol, Shanghai, Peoples R China
[17] RemeGen Co Ltd, Rheumatol, Yantai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Clinical Trials; Randomized control trial; Sjogren syndrome;
D O I：
10.1136/annrheumdis-2023-eular.1728
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0142
引用
收藏
页码：94 / 95
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY
    Wang, L.
    Li, J.
    Xu, D.
    Fang, J.
    Van Vollenhoven, R.
    Zhang, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 90 - 91
  • [2] Efficacy and Safety of Telitacicept in Primary Sjogren's Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
    Xu, Dong
    Zhang, Shangzhu
    Huang, Cibo
    Huang, Chenghui
    Qin, Li
    Li, Xiaomei
    Chen, Meiqing
    Liu, Xiumei
    Liu, Yi
    Li, Zhijun
    Hu, Jiankang
    Bao, Chunde
    Wei, Wei
    Tian, Jing
    Duan, Xinwang
    Fang, Jianmin
    Zeng, Xiaofeng
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4002 - 4004
  • [3] Efficacy and safety of telitacicept in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial
    Xu, Dong
    Fang, Jianmin
    Zhang, Shangzhu
    Huang, Cibo
    Huang, Chenghui
    Qin, Li
    Li, Xiaomei
    Chen, Meiqing
    Liu, Xiumei
    Liu, Yi
    Li, Zhijun
    Hu, Jiankang
    Bao, Chunde
    Wei, Wei
    Tian, Jing
    Duan, Xinwang
    Zeng, Xiaofeng
    RHEUMATOLOGY, 2024, 63 (03) : 698 - 705
  • [4] Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study
    Merrill, Joan
    Werth, Victoria
    Furie, Richard
    van Vollenhoven, Ronald
    Petronijevic, Milan
    Velasco Zamora, Benito
    Majdan, Maria
    Irazoque-Palazuelos, Fedra
    Weiswasser, Michael
    Korish, Shimon
    Schafer, Peter
    Liu, Zhaohui
    Gaudy, Allison
    Agafonova, Nataliya
    Delev, Nikolay
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [5] Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
    Merrill, Joan T.
    Wallace, Daniel J.
    Wax, Stephen
    Kao, Amy
    Fraser, Patricia
    Chin, Wai
    Isenberg, David A.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [6] Efficacy and safety of iguratimod on patients with primary Sjogren's syndrome: a randomized, placebo-controlled clinical trial
    Shao, Q.
    Wang, S.
    Jiang, H.
    Liu, L.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 (02) : 143 - 152
  • [7] EFFICACY AND SAFETY OF ATACICEPT IN PATIENTS WITH HIGH DISEASE ACTIVITY IN A 24-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE IIB STUDY (ADDRESS II)
    Merrill, J. T.
    Wallace, D. J.
    Kao, A.
    Mateo, C. Vazquez
    Fraser, P. A.
    Chang, P.
    Isenberg, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 856 - 856
  • [8] A Phase 2, randomized, placebo-controlled, 24-Week study of the efficacy and safety of losmapimod in treating subjects with FSHD: ReDUX4
    Mellion, M.
    Tawil, R.
    Ronco, L.
    Rahilly, A.
    Rojas, A.
    Odueyungbo, A.
    Wagner, K.
    Statland, J.
    Wang, L.
    Genge, A.
    Gibson, S.
    Goyal, N.
    Hamel, J.
    Johnson, N.
    Lochmuller, H.
    LoRusso, S.
    Pestronk, A.
    Sacconi, S.
    Shieh, P.
    Cadavid, D.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S112 - S112
  • [9] Remibrutinib (LOU064) in Sjogren's Syndrome: Safety and Efficacy Results from a 24-Week Placebo-controlled Proof-of-Concept Study
    Dorner, Thomas
    Szanto, Antonia
    Tseng, Jui-Cheng
    Kaul, Martin
    Pylvaenaeinen, Ilona
    Hanser, Malika
    Abdallah, Nasri
    Cenni, Bruno
    Siegel, Richard
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2211 - 2214
  • [10] DESIGNING OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJOGREN'S SYNDROME
    Hubbard, J.
    Campbell, K.
    Sivils, K.
    Hoffman, R.
    Lo, K. H.
    Leu, J. H.
    Bowman, S.
    Liva, S.
    Zuraw, Q.
    Stevens, A. M.
    Ling, L.
    Karcher, K.
    Ramchandren, S.
    Sun, H.
    Scofield, R. H.
    Seror, R.
    Wallace, D. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 892 - 893
12345